Profound Medical Corp PROF 深 沪
已收盘 07-02 16:00:00 美东时间
6.81
+0.060
+0.89%
华盛通- 最 高6.90
- 今 开6.83
- 成交量 2.32万股
- 最 低 6.75
- 昨 收 6.75
- 总市值 2.47亿
- 52周最高 8.95
- 市盈率 静 --
- 换手率 0.06%
- 52周最低 3.76
- 委 比 33.55%
- 总股本 3633.76万
- 历史最高 28.97
- 量 比 0.61
- 振 幅 2.22%
- 历史最低 3.10
- 每 手 1
- 风险率 1.01%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Telix Pharma Enters Into LOI To Pursue Collaborations With EDAP And Profound Medical To Explore Investigational Use Of Telix's PSMA-PET1 Imaging Agents Gozellix And Illuccix With Robotic HIFU, And Other Image-Guided Therapies To Treat Prostate Cancer
Telix to partner with companies developing advanced minimally invasive and image-guided ablative technologies for prostate cancer.Initial focus on patient selection, treatment planning and post-treatment monitoring;
05-15 18:33
Telix Announces Collaborations to Explore PSMA-PET Imaging in Emerging Prostate Cancer Treatment Approaches
<p>Telix Pharmaceuticals has entered into collaborations with EDAP TMS and Profound Medical to integrate PSMA-PET imaging with advanced minimally invasive and image-guided therapies for prostate cancer. The aim is to enhance treatment planning, efficacy, and monitoring while reducing side effects. This partnership focuses on emerging therapies like robotic HIFU and MRI-guided TULSA ablation, aiming to personalize care and improve patient outcomes...
05-15 10:30
Profound to Showcase TULSA-PRO®, the TULSA Procedure™ and the Future of iMRI at AUA2026
Profound Medical Corp. will highlight the TULSA Procedure in four oral presentations at the AUA 2026 Annual Meeting, focusing on MRI-guided prostate cancer ablation. The company also announced plans to integrate PSMA PET molecular imaging with TULSA-PRO to enhance treatment planning and monitoring, aiming to improve precision and patient outcomes. Attendees are invited to visit Profound's booth for demonstrations of TULSA-PRO and MRI technology.
05-14 11:00
Profound Medical Sees FY2026 Sales $25.000M
Profound Medical (CSE2: PRN) sees FY2026 sales of $25.000 million.
05-08 04:51
Why Medtech Giants Are Quietly Paying Up for AI Diagnostics
ISSUED ON BEHALF OF VENTRIPOINT DIAGNOSTICS LTD. VANCOUVER, BC, April 29, 2026 /PRNewswire/ -- USANewsGroup.com News Commentary – There's a quiet bidding war underway for AI diagnostics, and...
04-29 22:30
Profound Medical Congratulates Texas Prostate on Achieving 100th TULSA Procedure™ Milestone
Toronto, March 27 - Profound Medical announced that Texas Prostate, led by Dr. James Cochran, has completed its 100th TULSA Procedure at Dallas Medical Center. The TULSA Procedure, utilizing real-time MRI guidance and thermography, offers enhanced precision and safety for treating prostate diseases. Since collaborating with Dallas Medical Center, Dr. Cochran saw a 500% increase in procedures, highlighting the procedure's versatility across prosta...
03-27 11:45
Top 3 Health Care Stocks That Are Set To Fly In March
Opportunity to buy undervalued health care stocks. RSI is a momentum indicator that compares strength on up and down days. Here's a list of oversold stocks with RSI near or below 30.
03-20 18:23
CAPTAIN Trial Comparing Profound’s MRI-Guided TULSA Procedure™ to Robotic Radical Prostatectomy Successfully Meets Primary Safety Endpoint, Preservation of Erectile Function and Urinary Continence
Profound Medical Corp. announced the superior safety outcomes of the TULSA Procedure compared to robotic radical prostatectomy (RP) in men with localized prostate cancer in the CAPTAIN trial, exceeding enrollment targets with 211 patients. At 6 months, 50% of TULSA patients preserved erectile function and continence vs. 24% with RP (p<0.05). Urinary continence rates were 84% for TULSA vs. 49% for RP, and erectile function was preserved in 56% of ...
03-13 14:30
Profound Medical Earnings Call Maps Path to Profit
Profound Medical (($TSE:PRN)) has held its Q4 earnings call. Read on for the ma...
03-08 08:30
Profound Medical Q4 EPS $(0.27) Beats $(0.38) Estimate, Sales $5.977M Miss $10.532M Estimate.
Profound Medical (TSX:PRN) reported quarterly losses of $(0.27) per share which beat the analyst consensus estimate of $(0.38) by 28.95 percent. This is a 35 percent decrease over losses of $(0.20) per share from the
03-06 05:28
